Pfizer Stock News

The neutralising antibody response generated by the Pfizer vaccine may 41 times less effective against the omicron variant than the initial Covid virus type, an early study has suggested.

THE PFIZER coronavirus vaccine could be up to 40 TIMES less effective against Omicron rather than the original Covid strain, new tests have shown. The super mutant Covid strain has been sweeping across the globe after South Africa first alerted the world to it on November 23. Experts already discovered that people who have previously []

Aldebaran Financial Inc. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 15.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,602 shares of the biopharmaceutical companys stock after purchasing an additional 904 shares during the period. Aldebaran Financial Inc.s holdings in []

A YEAR ago today the NHS made history when Maggie Keenan became the first person in the world to receive a Pfizer jab, outside a clinical trial, launching the first national Covid vaccination programme. That jab, delivered by matron May Parsons in Coventry’s University Hospital was watched around the globe, a moment of hope for […]

Omicron Study Scare Stuns ''Face-Ripping'' FOMO Short-Squeeze Everything was awesome today UNTIL... Headlines from a South African study hit, suggesting a 40-fold reduction in neutralization capacity of the Pfizer vaccine vs Omicron . .. which suggest hospitals will get overwhelmed (due to its hyper-transmissibility) but it is notably less severe (especially for healthy people)... Omicrons ability to evade vaccine and infection-induced immunity is robust but not complete, said the research head of a laboratory at the Africa Health Research Institute in South Africa. ...and that sent stocks lower late in the day (although still a good day overall)... And slammed ''recovery'' stocks relative to ''stay at home'' stocks... But then again... it wouldn''t be the US equity market if a last minute total buying-panic didn''t send the Nasdaq up 100 points in 4 minutes... * * * As we detailed earlier...A China RRR cut? Omicron anxiety easing? Whatever it was, bubble markets exploded higher today...

Five people on board a Sydney Harbour cruise on Friday night have tested positive to Covid, with two likely the new variant. Follow all the day’s news

Pfizer Accused Of Spreading "Misinformation" About Rival COVID Jabs Leave it to the Brits to highlight all the flaws inherent in the US-led effort to develop (and reap immense profits from) COVID vaccines while the WTO holds the line on denying the sharing of IP rights to allow developing nations to produce their own jabs. The UK''s Channel 4 has produced a new documentary that exposes Pfizer''s efforts to undermine its rivals, including AstraZeneca, which developed a jab in the UK with help from Oxford University. And teasers from this new doc, released late Monday, purports to show that Pfizer criticized AZ in a presentation where the company said the rival jab was potentially dangerous. Furthermore, the speakers claimed AZ''s jab could cause cancer and was not safe for immunosuppressed patients. The presentation in question was delivered in Canada sometime last year, although it''s unclear whether it was a one-off event or whether the speaker had made the claim multiple times. The program, entitled "Vaccine Wars: The Truth About Pfizer", will air in its entirety on Friday.

By Anthony Lambrou, Pfizer Continue reading on Global Coalition on Aging »

Related Stocks: BBBY , F , AMRN , CZR , WYNN , PFE , ROKU , COIN , NIO , TJX , PLTR , AAL ,

DUBLIN--(BUSINESS WIRE)--The "Immunosuppressants Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global immunosuppressants market is expected to grow from $15.04 billion in 2020 to $16.5 billion in 2021 at a compound annual growth rate (CAGR) of 9.7%. The market is expected to reach $25.33 billion in 2025 at a CAGR of 11%. Major players in the immunosuppressant market are Astellas Pharma, GlaxoSmithKline, Bristol Mye

Both inhaled vaccines are intended to act as boosters to be administered to participants who have previously received two doses of a COVID-19 mRNA vaccine such as Pfizer or Modernas.

DUBLIN--(BUSINESS WIRE)--The "Psoriatic Arthritis Treatment Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global psoriatic arthritis treatment market is expected to grow from $7.26 billion in 2020 to $7.89 billion in 2021 at a compound annual growth rate (CAGR) of 8.7%. The market is expected to reach $11.34 billion in 2025 at a CAGR of 9%. Major players in the psoriatic arthritis treatment market are AbbVie, Amgen

Ade LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 2.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,394 shares of the biopharmaceutical companys stock after selling 300 shares during the period. Pfizer makes up 0.5% of Ade LLCs holdings, making the stock its []

Pfizer CEO Albert Bourla addresses a press conference after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021. John Thys | Pool | Reuters Pfizer CEO Albert Bourla on Tuesday said the omicron variant of the virus that causes [] The post Pfizer CEO says omicron appears milder but could lead to more mutations appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

Docetaxel Industry Outlook 2021: Docetaxel injection is either used alone or in combination with other medications to treat certain types of lung, breast, stomach, prostate cancers. Actavis Pharma Company, Sun Pharma Globa, Pfizer Laboratories Div Pfizer Inc., genus Pharmaceuticals, LLC, and